Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 105 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Exacerbation Copd Clear all
Completed Phase 3 Interventional Results available

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

NCT02296138
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
olodaterol, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
7,903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
117
States / cities
Andalusia, Alabama • Birmingham, Alabama • Florence, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 22, 2026, 11:48 PM EDT
Not listed No phase listed Observational

Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD

NCT05865184
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease, COPD Exacerbation, CHF, Congestive Heart Failure
Interventions
Data collection
Other
Lead sponsor
Sensorum Health Inc.
Industry
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 22, 2026, 11:48 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AQX-1125 in Unstable COPD

NCT01954628
View directory record Official record
Conditions
COPD
Interventions
AQX-1125, Placebo
Drug
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Industry
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 22, 2026, 11:48 PM EDT
Completed No phase listed Observational

Phenotypic Measurements and Their Relation to Disease Exacerbation in COPD Patients

NCT03300739
View directory record Official record
Conditions
COPD Exacerbation, Copd
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 22, 2026, 11:48 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02164513
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
10,355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
269
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 22, 2026, 11:48 PM EDT
Terminated No phase listed Observational

Acute Exacerbation of COPD and Physical Activity - Preliminary Study

NCT01871246
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 22, 2026, 11:48 PM EDT
Completed Phase 3 Interventional Results available

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

NCT01120691
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, NVA237, tiotropium, Salbutamol/albuterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Fairhope, Alabama • Florence, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Oct 22, 2026, 11:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

AECOPD and Nutritional Supplementation in COPD

NCT06801964
View directory record Official record
Conditions
Obstructive Pulmonary Disease, Exacerbation Copd
Interventions
Stable isotope infusion, Protein and Fish Oil, Protein and Olive Oil, Carbohydrate and Olive Oil
Other · Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 22, 2026, 11:48 PM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 22, 2026, 11:48 PM EDT
Completed No phase listed Observational

ICS/LABA Adherence and COPD Exacerbation

NCT02446041
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Non-Interventional Study
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 22, 2026, 11:48 PM EDT
Recruiting No phase listed Observational

COPD Exacerbation Follow Up

NCT07118306
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Not listed
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
40 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Park Ridge, Illinois • Cherry Hill, New Jersey • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 11:48 PM EDT
Active, not recruiting Not applicable Interventional

Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke

NCT07118189
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Exacerbation of COPD, Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
N95 masks and indoor air cleaner
Device
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 22, 2026, 11:48 PM EDT
Terminated Phase 4 Interventional Results available

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

NCT03219866
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 22, 2026, 11:48 PM EDT
Completed Phase 2 Interventional

Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

NCT06940154
View directory record Official record
Conditions
COPD Acute Exacerbation
Interventions
Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
Combination Product · Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Valencia, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 11:48 PM EDT
Terminated Not applicable Interventional

Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD

NCT03255057
View directory record Official record
Conditions
Acute Exacerbation of COPD
Interventions
Hemolung Respiratory Assist System, Invasive mechanical ventilation
Device
Lead sponsor
Alung Technologies
Industry
Eligibility
40 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
32
States / cities
Sacramento, California • Denver, Colorado • Newark, Delaware + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 22, 2026, 11:48 PM EDT
Not yet recruiting Phase 4 Interventional

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)

NCT07721922
View directory record Official record
Conditions
COPD Exacerbation
Interventions
Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline), Albuterol sulfate, Ipratropium Bromide
Drug · Other
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 11:48 PM EDT
Terminated No phase listed Observational

COPD Exacerbation Blood and Urine Biomarkers Study

NCT03823443
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Acute Exacerbation Copd, Alpha-1 Anti-trypsin Deficiency
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 22, 2026, 11:48 PM EDT
Completed No phase listed Observational

Effect of Remote Physiologic Monitoring (RPM) on Outcomes in COPD Patients

NCT05518981
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Respiratory Remote Patient Monitor (Spire Health Tag)
Device
Lead sponsor
Spire, Inc.
Industry
Eligibility
Not listed
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 22, 2026, 11:48 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

NCT00419744
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
92
States / cities
Jasper, Alabama • Mobile, Alabama • Tucson, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 22, 2026, 11:48 PM EDT
Recruiting No phase listed Observational

Early Detection of COPD Exacerbations Using Home Monitoring Device

NCT07554352
View directory record Official record
Conditions
COPD Exacerbation
Interventions
RespirAI
Device
Lead sponsor
RespirAI US Inc
Industry
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 11:48 PM EDT
Completed No phase listed Observational Results available

ProAir Digihaler in COPD Disease Management: A Real World Study

NCT04821869
View directory record Official record
Conditions
COPD, COPD Exacerbation Acute
Interventions
ProAir Digihaler, Digihaler
Drug · Device
Lead sponsor
Pulmonary Research Institute of Southeast Michigan
Other
Eligibility
45 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 22, 2026, 11:48 PM EDT
Recruiting Phase 4 Interventional

This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

NCT07587658
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Mullica Hill, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 11:48 PM EDT
Withdrawn Phase 2 Interventional

Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels

NCT00851370
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Omalizumab (Xolair), Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 22, 2026, 11:48 PM EDT
Completed No phase listed Observational

Healthy At Home Pilot

NCT06000696
View directory record Official record
Conditions
COPD, COPD Exacerbation, Emphysema or COPD
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 22, 2026, 11:48 PM EDT